Status: Recruiting
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Participants needed: 122
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AtlasMedx, IncorporatedUpdated: May 1, 2025Locations: 4
Eligibility criteria
Patient is intolerant of existing therapy(ies) known to provide clinical benefit... [+6]
Receiving cancer treatment at the time of enrollment [+4]